Rising Prevalence of Cancer is anticipated to fuel the Growth of the Global CAR T Cell Therapy Market at a CAGR of 14.5% during the Forecast Period

Market Research Future (MRFR) has published a cooked research report on the “Global CAR T Cell Therapy Market” that contains information from 2023 to 2032. The Global CAR T Cell Therapy Market is estimated to register a CAGR of 14.5% during the forecast period of 2023 to 2032.

Market Highlights

Global CAR T Cell Therapy Market is accounted to register a CAGR of 14.5% during the forecast period and is estimated to reach USD 7.2 Billion by 2032.

CAR T cell therapy, or Chimeric Antigen Receptor T cell therapy, is an innovative immunotherapy approach that harnesses the power of a patient's immune system to fight cancer. It involves extracting a patient's T cells, a type of immune cell, and genetically modifying them to express chimeric antigen receptors (CARs) on their surface. These CARs are designed to recognize specific cancer antigens and activate the T cells to selectively target and destroy cancer cells in the body. Once the modified CAR T cells are infused back into the patient, they multiply and attack the cancer, potentially leading to significant and durable remission in certain types of hematologic malignancies. CAR T cell therapy represents a groundbreaking advancement in cancer treatment, offering hope to patients who have limited or no effective treatment options.

Key Players:

MRFR recognizes the following companies as the key players in the Global CAR T Cell Therapy Market— Bluebird Bio, Intellia Therapeutics, Noile-Immune Biotech, Celgene Corporation, Bellicum Pharmaceuticals Inc, Novartis International, Celyad, Cellectis, Servier Laboratories, Pfizer Inc, Caribou Biosciences Inc, Mereck, and Amgen Inc.

Segment Analysis

The Global CAR T Cell Therapy Market has been segmented based on Target Antigen, and Application.

Based on Target Antigen, the market is segmented into CD19, CD22. The CD19 category dominates the CAR T cell therapy market due to its exceptional success in treating B-cell malignancies. CD19 is a surface protein found on B cells, including cancerous B cells in diseases like acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL).

Based on Application, the market is segmented into Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia. The Diffuse Large B-cell Lymphoma category dominates the CAR T cell therapy market due to its high prevalence and significant clinical response rates.

Explore In-depth Details: CAR T Cell Therapy Market Research Report

Regional Analysis

The Global CAR T Cell Therapy Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global CAR T Cell Therapy Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global CAR T Cell Therapy Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Global CAR T Cell Therapy Market comprises of Middle East, Africa, and Latin America.

According to market analysis, the CAR-T cell gene therapy market is projected to exhibit excellent Based on the analysis of the CAR-T cell gene therapy market, it is evident that the North American region is exhibiting strong indications of remarkable growth throughout the specified period. With an anticipated global compound annual growth rate (CAGR) of 36.4%, North America is poised to emerge as a key driver of the market's expansion. Similarly, the European market is experiencing dynamic shifts in trends and witnessing an increased adoption of advanced technologies, which are expected to contribute significantly to the growth rate of the CAR-T cell therapy market.

Furthermore, the recommended approvals of Yescarta and Kymriah by the European Medicine Agencies (EMA) are playing a crucial role in shaping the market's trajectory. These positive attributes associated with the approved therapies are likely to foster greater acceptance and utilization, ultimately bolstering the overall growth of the CAR-T cell therapy market. The optimistic outlook extends until the forecast period concludes in 2028, wherein these factors collectively create a favorable environment for sustained development and expansion within the industry.

Key Findings of the Study

• The European market is experiencing transformative trends and increased adoption of advanced technologies, contributing to a significant growth rate in the CAR-T cell therapy market. The approval of Yescarta and Kymriah by the European Medicine Agencies (EMA) further enhances the positive outlook, providing a boost to the market's overall growth.


• Based on the Target Antigen, the Market has been segmented into CD19 holding the largest market in 2023.


• Bluebird Bio, Intellia Therapeutics, Noile-Immune Biotech, Celgene Corporation, Bellicum Pharmaceuticals Inc, Novartis International, Celyad, Cellectis, Servier Laboratories, Pfizer Inc, Caribou Biosciences Inc, Mereck, and Amgen Inc.